CancerVision

Turning
DNA data
into action
with **whole
genome
insights**

INOCRAS

WE ARE INOCRAS

Unlock the new era of whole genome insights with Inocras

Inocras is on a mission to improve how the world diagnoses and treats genetically driven diseases. Specializing in cancer and rare diseases, our whole genome bioinformatics platform offers a comprehensive view of a person's genetic makeup, combined with actionable clinical insights for better patient care.

WHAT WE DO

- We perform whole genome sequencing to get a comprehensive view of the genome and identify pathogenic and likely pathogenic mutations
- Our patent-protected technology and proprietary bioinformatics pipeline enables us to interpret massive WGS data into actionable insights
- We specialize in cancer and rare disease diagnostics, and tested with more than 13,500 patients

WHO WE SERVE

Our goal is to provide user-friendly services with the power of WGS insights.

Patients
- WGS test report
- Clinical trial matching
- Genetic counseling
- End-to-end digital experience

Physicians
- WGS test report
- Clinical trial matching
- Expert support
- Digital ordering system

Researchers
- Fit-for-purpose research service menu
- Customized support with expert advisory
- Latest sequencing technology

OUR PARTNERS

MASSIVEBIO · SAMSUNG LIFE SERVICE · Guide Genetics · ASAN Medical Center · ULTIMA GENOMICS · SCL 서울의과학연구소 · DNAvisit

MORE INSIGHTS, MORE CLARITY

Why whole genome?

Recent studies revealed that complicated mutations are often not captured in standard panel testing and whole exome sequencing. Standard panel testing looks at less than 0.1% of your genome[1], and whole exome sequencing looks at only 1-2%[2], leaving plenty of room for unanswered questions.

Whole genome sequencing looks at > 99% of the genome, capturing the whole genomic landscape, including both common and rare mutations in coding and non-coding regions, as well as complex mutations. This advanced approach offers deeper insights than many conventional genetic tests to inform the next steps on your patients' health journeys.

CancerVision distinguishes between germline and somatic variants. Understanding the origin of the mutation is critical for a personalized approach to selecting treatment options.

TARGETED PANEL SEQUENCING



<0.1% genome-wide coverage

Limited number of point mutations

Limited copy number variations

Limited structural variations

WHOLE EXOME SEQUENCING



1-2% genome-wide coverage

Limited number of point mutations

Limited copy number variations

Limited structural variations

Non-coding areas not covered

WHOLE GENOME SEQUENCING



>99% genome-wide coverage

More point mutations identified

More accurate, genome-wide copy number variations

Genome-wide coverage of structural variations

Non-coding areas also covered

We relieve your diagnostic burden so you can spend more time caring for your patients

Our goal is to be a resource for you beyond top-tier genetic testing. We're here to enhance your ability to support your patients by providing actionable insights through the translation of complex data and findings.

We capture more than what conventional NGS captures
CancerVision has been clinically validated and detected 100% of the variants[3] identified by the clinically validated TruSight Oncology 500 (Illumina) NGS target oncology panel test.

We provide highly sensitive genome-wide signatures
CancerVision is able to detect accurate genomic pattern-based markers and provides highly accurate HRD detection – without adding any other tests (based on 688 cancer patient cases).

Actionable insights
Our proprietary high-performing bioinformatics algorithm thoroughly analyzes a patient's genome data and highlights the findings highly relevant to clinical utility. In one study, more than 70%[4] of our WGS reports yielded clinically relevant insights, including actionability for therapeutic options and clinical clarity.

More findings for more clarity
CancerVision provides broader insights than many conventional genetic tests and reduces the likelihood of false positives, so you can provide more clarity for your patients.

1 Shin K, et al. Clinical Utility of Whole-Genome Analysis as One-for-All Test for Breast Cancer: A Case Series. Case Rep Oncol. 2024 Feb 23;17(1):317-328. doi: 10.1159/000536087. PMID: 38404405; PMCID: PMC10890799.

2 Warr Aet al. Exome Sequencing: Current and Future Perspectives. G3 (Bethesda). 2015 Jul 2;5(8):1543-50. doi: 10.1534/g3.115.018564. PMID: 26139844; PMCID: PMC4528311.

3 Lee S et al. medRxiv 2023. https://doi.org/10.1101/2023.12.20.23300156

4 Kim R et al. medRxiv 2024.02.08.24302488. https://doi.org/10.1101/2024.02.08.24302488

Get the data you need to support a diagnosis

CancerVision is a whole genome sequencing test for patients with solid tumors that may have been recently diagnosed, are recurring or metastatic, or aren't responding to treatment. It is also for patients who want to find more answers about the genetic drivers of their cancer.

We offer you and your patients whole genome coverage, actionable findings, clinical trial matching and expert support to provide the best care possible.

- **A 2-in-1 test:** Paired somatic-germline testing
- **Liquid biopsy** for cancer profiling with cfDNA when tissue sample fails
- **Target-enhanced whole-genome sequencing:** An average of 40x depth WGS backbone with focused exploration of an average of 500x depth for 500 key biomarker genes
- **All types of alterations:** Single nucleotide variants (SNVs), small indel variants, large structural variants (SV), and copy number variants (CNV), including variants in non-coding regions
- **Genome-wide signatures:** Our proprietary algorithms for Tumor Mutational Burden (TMB), Microsatellite instability (MSI), Homologous recombination deficiency (HRD), and more
- **Germline WGS** reports pathogenic germline variants according to ACMG guidelines
- **Clinical trial matching support**
- **Expert consultation available upon request** (including Molecular Tumor Board support)
- **2-week turnaround time****

**2 weeks from receipt of the blood samples at our lab.

How can I order Cancer**Vision**?

Ordering a test is quick and easy at our provider order portal.

Step 1

Start an online order by filling out the test requisition form and we will send our kits to your office.

Step 2

Use our supplied sample collection kit and instructions to collect a blood sample from your patient for testing.

Step 3

Ship the blood sample directly to us.

Step 4

Receive the test results via email and fax. You can also access all test results you ordered in our online portal.

If you need support during the process,

contact us at **inquiry@inocras.com.**

INOCRAS

INOCRAS.COM
6330 Nancy Ridge Drive, Suite 106
San Diego, CA 92121

IP77-0824